ATE543831T1 - Antibakterielle wirkstoffe enthaltende konjugate von glykopeptiden und membranassoziierenden peptiden - Google Patents

Antibakterielle wirkstoffe enthaltende konjugate von glykopeptiden und membranassoziierenden peptiden

Info

Publication number
ATE543831T1
ATE543831T1 AT01980689T AT01980689T ATE543831T1 AT E543831 T1 ATE543831 T1 AT E543831T1 AT 01980689 T AT01980689 T AT 01980689T AT 01980689 T AT01980689 T AT 01980689T AT E543831 T1 ATE543831 T1 AT E543831T1
Authority
AT
Austria
Prior art keywords
membrane
glycopeptides
conjugates
agents
active ingredients
Prior art date
Application number
AT01980689T
Other languages
English (en)
Inventor
Matthew Cooper
Jason Betley
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Application granted granted Critical
Publication of ATE543831T1 publication Critical patent/ATE543831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT01980689T 2000-11-03 2001-11-02 Antibakterielle wirkstoffe enthaltende konjugate von glykopeptiden und membranassoziierenden peptiden ATE543831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0026924.1A GB0026924D0 (en) 2000-11-03 2000-11-03 Antibacterial agents
PCT/GB2001/004867 WO2002036612A1 (en) 2000-11-03 2001-11-02 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane-associating elements

Publications (1)

Publication Number Publication Date
ATE543831T1 true ATE543831T1 (de) 2012-02-15

Family

ID=9902519

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01980689T ATE543831T1 (de) 2000-11-03 2001-11-02 Antibakterielle wirkstoffe enthaltende konjugate von glykopeptiden und membranassoziierenden peptiden

Country Status (10)

Country Link
US (1) US7078380B2 (de)
EP (1) EP1334117B1 (de)
JP (1) JP4209673B2 (de)
AT (1) ATE543831T1 (de)
AU (2) AU2002212482B2 (de)
CA (1) CA2426012C (de)
DK (1) DK1334117T3 (de)
ES (1) ES2381649T3 (de)
GB (1) GB0026924D0 (de)
WO (1) WO2002036612A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220936D0 (en) 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents
CN100506841C (zh) * 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
JP4524671B2 (ja) * 2003-10-29 2010-08-18 東亞合成株式会社 抗菌ペプチド及びその利用
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
AU2006225382B2 (en) * 2005-03-21 2013-05-09 Cytacoat Ab An antimicrobial agent comprising a cysteine compound covalently bound to a substrate, in particular by binding through an S-S bridge via a spacer molecule
JP2009526046A (ja) 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ 新規分子
JP2009529530A (ja) * 2006-03-09 2009-08-20 インフラザイム・ファーマシューティカルズ・リミテッド 新規の抗生物質組成物
JP5158716B2 (ja) * 2006-08-24 2013-03-06 国立大学法人群馬大学 乳酸残基を含有するデプシペプチド
US20090246250A1 (en) * 2008-03-27 2009-10-01 Affinergy Coating compositions having improved performance
US8404636B2 (en) 2008-07-17 2013-03-26 George Mason Intellectual Properties, Inc. Targeted delivery of antimicrobial agents
EP3384938A1 (de) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Manipulierte nukleinsäuren und verfahren zur verwendung davon
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2833923A4 (de) 2012-04-02 2016-02-24 Moderna Therapeutics Inc Modifizierte polynukleotide zur herstellung von proteinen
CN104418941B (zh) * 2013-08-19 2017-11-07 爱斯医药科技(南京)有限公司 万古霉素衍生物、制备方法及其应用
GB201402267D0 (en) * 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
WO2015164666A1 (en) * 2014-04-23 2015-10-29 Avrygen Corporation Nanoparticles for targeted gene therapy and methods of use thereof
GB201415776D0 (en) * 2014-09-05 2014-10-22 Singh Ishwar And Taylor Edward New antibacterial products
WO2016191658A1 (en) * 2015-05-28 2016-12-01 President And Fellows Of Harvard College Inhibitors of bacterial glycosyl transferases
KR20180101341A (ko) 2015-11-10 2018-09-12 비스테라, 인크. 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
US11084833B2 (en) 2016-10-10 2021-08-10 The Johns Hopkins University Antibacterial agents against D,D- and L,D-transpeptidases
EP3571223B1 (de) 2017-01-18 2024-09-18 Visterra, Inc. Antikörpermolekularzneimittelkonjugate und verwendungen davon
CN110240656A (zh) * 2019-04-24 2019-09-17 中山大学附属第三医院 一种融合蛋白及其制备方法与应用
JP2023521319A (ja) 2020-04-03 2023-05-24 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067099A (en) * 1955-09-16 1962-12-04 Lilly Co Eli Vancomycin and method for its preparation
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5834430A (en) * 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
US5919756A (en) * 1996-06-28 1999-07-06 Eli Lilly And Company Amides
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
EP1212094A2 (de) * 1999-04-23 2002-06-12 St. Jude Medical, Inc. Abgabe von antimikrobieller toxine
US20040072743A1 (en) 2000-04-06 2004-04-15 Christensen Jeppe Viggo Pharmaceutical composition of modified pna molecules

Also Published As

Publication number Publication date
DK1334117T3 (da) 2012-05-29
JP2004513132A (ja) 2004-04-30
AU1248202A (en) 2002-05-15
WO2002036612A1 (en) 2002-05-10
US7078380B2 (en) 2006-07-18
AU2002212482B2 (en) 2006-09-21
ES2381649T3 (es) 2012-05-30
US20040106544A1 (en) 2004-06-03
GB0026924D0 (en) 2000-12-20
EP1334117A1 (de) 2003-08-13
JP4209673B2 (ja) 2009-01-14
CA2426012A1 (en) 2002-05-10
CA2426012C (en) 2013-06-11
EP1334117B1 (de) 2012-02-01

Similar Documents

Publication Publication Date Title
ATE543831T1 (de) Antibakterielle wirkstoffe enthaltende konjugate von glykopeptiden und membranassoziierenden peptiden
ATE243042T1 (de) Biologisch aktive verbindungen aus ganoderma pfeifferi dms 13239
DE60004803D1 (de) Pulmonare abgabe von protonierter/angesäuerter nukleinsäure
NO976028L (no) Fremgangsmåte for kontroll av antibiotika resistente gram positive bakterier og behandling av infeksjon
BR0111718A (pt) Peptìdeos quimicamente modificados, composições e métodos de produção e uso
ATE158818T1 (de) Auf proteinbasis beruhendes liefersystem
WO2000034265A3 (en) Quinoline-indole antimicrobial agents
DE69610424D1 (de) Auf histatin basierende, gegen pilze und bakterien gerichtete peptide
ES2170239T3 (es) Peptidos antifungicos de d-aminoacidos basados en histatina.
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
BR9205760A (pt) Proteínas antimicrobiais, proteína pura MJ-AMPI, proteínas puras, sequência de DNA recombinante, vetor, sistema biológico, plantas, composição antimicrobial, processo para combater fungos ou bactérias e processo de extração para produzir proteínas biocidamente ativas
ATE500277T1 (de) Hybridpeptide für die behandlung von bacteraemie und sepsis
EP1019084A4 (de) Neue antimikrobielle polypeptide und verfahren für ihre verwendung.
ATE228370T1 (de) Synthetische peptide als fungizid und antibiotika
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE60231825D1 (de) Behandlung von infektionen verursacht von mikroorganismen
EA200701384A1 (ru) Антибиотик 107891, его факторы a1 и a2, фармацевтически приемлемые соли и композиции и их применение
TW200510541A (en) Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
ATE376557T1 (de) Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika
ATE285786T1 (de) Säugetierabkömmliche peptide zur behandlung von mikrobiellen infektionen
DE69333781D1 (de) Biozide chitin bindende proteine
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
CA2301872A1 (en) 8a-azalides as veterinary antimicrobial agents
HUP0000146A2 (hu) Eljárás Streptococcus pneumoniae-fertőzés kezelésére